To develop and externally validate a predictive model for detection of significant prostate cancer.
Patients and Methods
Development of the model was based on a prospective cohort including 393 men who underwent multiparametric magnetic resonance imaging (mpMRI) before biopsy. External validity of the model was then examined retrospectively in 198 men from a separate institution whom underwent mpMRI followed by biopsy for abnormal prostate-specific antigen (PSA) level or digital rectal examination (DRE). A model was developed with age, PSA level, DRE, prostate volume, previous biopsy, and Prostate Imaging Reporting and Data System (PIRADS) score, as predictors for significant prostate cancer (Gleason 7 with >5% grade 4, ≥20% cores positive or ≥7 mm of cancer in any core). Probability was studied via logistic regression. Discriminatory performance was quantified by concordance statistics and internally validated with bootstrap resampling.
Results
In all, 393 men had complete data and 149 (37.9%) had significant prostate cancer. While the variable model had good accuracy in predicting significant prostate cancer, area under the curve (AUC) of 0.80, the advanced model (incorporating mpMRI) had a significantly higher AUC of 0.88 (P < 0.001). The model was well calibrated in internal and external validation. Decision analysis showed that use of the advanced model in practice would improve biopsy outcome predictions. Clinical application of the model would reduce 28% of biopsies, whilst missing 2.6% significant prostate cancer.
Introduction
Prostate cancer is the third most frequent cause of cancer death in developed countries [1] . PSA screening has been introduced with the aim of reducing prostate cancer-related mortality, but the incidence of prostate cancer has more than doubled since the introduction of serum PSA testing and half to two-thirds of cases diagnosed by screening are thought to be over-detected [2, 3] .
Among men with elevated PSA levels, standard systematic prostate biopsy tends to detect both clinically significant and insignificant prostate cancer, in relatively equal proportions [4, 5] . The results of randomised controlled studies that evaluated the efficacy of prostate cancer screening have highlighted the need to reduce overdiagnosis of insignificant prostate cancer [6] [7] [8] . Therefore, a new diagnostic pathway is needed that selectively identifies men with significant prostate cancer, while reducing the number of unnecessary biopsies and detection of insignificant prostate cancer.
Firstly, an individualised screening algorithm using other available pre-biopsy information in addition to PSA level can result in a considerable reduction in unnecessary biopsies [5] . Multiparametric MRI (mpMRI) has emerged as a secondary screening tool that can further increase the specificity of detecting clinically significant prostate cancer, while maintaining a high sensitivity [9, 10] . Predictive nomograms are used widely in prostate cancer to aid with patient counselling and complex decisions regarding biopsy, but none to date have incorporated mpMRI data and none have achieved widespread routine use [11] .
The aim of the present study was to develop and externally validate a novel predictive model for detection of significant prostate cancer that incorporates mpMRI parameters and clinical data.
Patients and Methods
Between April 2012 and March 2014, 398 men were enrolled in this prospective study at St. Vincent's Clinic, Sydney, Australia. The men were aged >40 years, planned for biopsy for abnormal PSA level or DRE, and had a life-expectancy of >10 years. Institutional Review Board approval was granted (SVH12/007, SVH15/115) and informed consent was obtained from all patients before mpMRI and biopsy. Data were reported according to the Standards of Reporting for MRItargeted Biopsy Studies (START) criteria [12] .
Study Protocol
The study protocol was described in detail by Thompson et al. [9] . In summary, all men were clinically selected for biopsy with assessment of age, serum PSA, DRE, family history for prostate cancer (first relatives only), and previous biopsy. In all men, mpMRI was performed before prostate biopsy. All mpMRI were performed at two centres, with a 1.5-T magnet (b-value 0-800 s/mm 2 ) at centre 1 and 3-T magnet (b-value 0-1 500 s/mm 2 ) at centre 2, using the 'gold standard' European Society of Urogenital Radiology (ESUR) MRI protocol [13] (no endorectal coil was used). According to the study protocol, two radiologists double reported independently, and were blinded to each other. The standardised 5-point Prostate Imaging Reporting and Data System (PIRADS) version 1 scale was used, blind from biopsy outcomes [13] . General agreement (each scoring PIRADS 1 or 2, or 3-5) between the two radiologists was 75% and the quadratic weighted j was 0.63 [9] . Using objective criteria regions of interest (ROI) were assigned a score of 1-5 for each parameter (T2-weighted imaging, contrast-enhanced imaging and diffusion-weighted imaging) and then an overall impression ROI score (based on individual parameter scores). Prostate volume was based on mpMRI, calculated as: 0.52 9 length 9 width 9 height.
All patients underwent transperineal mapping biopsies (median of 30 cores with relative peri-urethral zone sparing and adjusted for volume) from 18 template locations. Urologists reviewed the mpMRI report and images, and collected two additional targeted cores from all ROI potentially under sampled by template biopsy using MRI/ TRUS-fusion biopsy or cognitive (manual MRI informed) transperineal grid-directed TRUS-guided biopsy as described previously [14] .
Histology from biopsies were processed and reported according to the International Society of Urological Pathology (ISUP) protocols by one subspecialist uro-pathologist (W.D.P.). For all cores, the length of cancer in millimetres, total core length in millimetres, and both primary and secondary Gleason grade was assigned. Significant prostate cancer on biopsy was defined as any prostate cancer of Gleason score 7-10 with >5% Gleason grade 4, ≥20% cores positive or ≥7 mm of prostate cancer in any core.
Characterisation of the External Validation Population
Medical records were retrospectively reviewed of 198 consecutive patients who had undergone mpMRI followed by TRUS-guided extended transperineal or transrectal prostate biopsies at Royal North Shore Private Hospital, Sydney, Australia between January 2013 and December 2014. All men with more than one series of random negative prostate biopsies and men with a prior positive biopsy were excluded. Indication for biopsy was abnormal PSA or DRE. Pre-biopsy serum PSA, DRE, age, prostate volume, prostate cancer family history, and mpMRI findings were assessed. For mpMRI evaluation, the standardised 5-point PIRADS scale was used, mpMRI was reported by one radiologist [13] . Prostate biopsies were taken according to the institution's protocol with a minimum of 12 cores, with cognitive (manual MRI informed) fusion-guided biopsy (median of 18 cores). All specimens were evaluated by one uro-pathologist (W.D.P.). Institutional Review Board approval was granted and informed consent was obtained from all patients (NSPHEC 2015-LNR-007).
Statistics
For model development, all potential predictors of significant prostate cancer [PIRADS score (1-5, continuous), age, PSA level, DRE (normal/abnormal), family history (yes/no), previous negative biopsy (yes/no), prostate volume, and significant prostate cancer (yes/no)], were assessed in all patients. Multicollinearity was tested between all variables, no multicollinearity was found. Multivariate logistic regression coefficients were used to develop the multivariable nomograms that predict the probability of significant prostate cancer. For continuous variables (age, PSA level and prostate volume), we used fractional polynomials to determine the appropriate functional form [15] . The area under the receiver operating characteristic curve (ROC) and discrimination slope were used to evaluate how the model could allow discrimination between patients with and without significant prostate cancer. We also assessed the calibration, that is the agreement between observed and predicted outcomes of the models [16] . Internal validation of the model was tested using 1 000 bootstrap resamples. The extent of over-or underestimation relative to the observed and predicted rate was explored graphically using calibration plots. The intercept indicates whether predictions are systematically too low or too high, and should ideally be zero. The calibration slope reflects the average effects of the predictors in the model and was estimated in a logistic regression model with the logit of the model predictions as the only predictor. For a perfect model, the slope equals 1 [16] .
Clinical utility was assessed via decision curve analysis. These analyses estimate a 'net benefit' for prediction models by summing the benefits (true positives biopsies) and subtracting the harms (false-positives biopsies). The latter are weighted by a factor related to the relative harm of a missed significant prostate cancer vs an unnecessary biopsy. The weighting is derived from the threshold probability of significant prostate cancer at which a patient would opt for biopsy. This threshold can vary from patient to patient. We concentrated on the net benefit for threshold probabilities between 5% and 35%. This implies a weight of 19:1 for the 5% threshold, and 9:1 for the 35% threshold for missing significant prostate cancer vs unnecessary biopsy. The reduction in number of biopsies using different probabilities was further assessed and related to the number and percentage of prostate cancer and significant prostate cancer. The interpretation of a decision curve is that the model with the highest net benefit at a particular threshold probability should be chosen. We compared four models: (i) a base model using only PSA to predict the presence of significant prostate cancer at biopsy; (ii) a multivariable model using the standard clinical predictors; (iii) an advanced model that adds the PIRADS score to the multivariable model ii; and (iv), a conditional model that is based on (a) those with a predicted probability of >60% in the multivariable model being biopsied, and those with a probability of >15% after including mpMRI being biopsied [17] . Reference strategies were biopsyall and biopsy-none.
For all analyses, two-sided P values <0.05 were considered to be statistically significant. Statistical analyses were performed with STATA version 14 (STATA Corp., College Station, TX, USA). Because of the very small amount of missing data [six men (1.5%) had missing data on any variable]; we did not include observations with missing data.
Results
In all, 393 patients with complete data were included in the development population and 198 men in the validation population. The patients' characteristics are presented in Table 1 . Men in the validation cohort were slightly older, had higher rates of PIRADS 3-5 lesions on mpMRI, and higher rates of significant prostate cancer (Table 1 ).
In the development population, 228 (58.0%) men were diagnosed with prostate cancer, of whom 149 (37.9%) had significant prostate cancer. In the multivariable analysis, age, PSA, DRE, prostate volume, a previous negative biopsy, and PIRADS score, were strongly associated with significant prostate cancer (all P ≤ 0.006). The analyses using fractional polynomials gave appropriate functional forms for PSA as 1/ PSA and 1/√(prostate volume). Family history (P = 0.08) was not associated with significant prostate cancer in the analysis and, therefore, not included in the multivariable models. Specifications of the prognostic multivariable and advanced prediction model are shown in Appendices S1 and S2.
Three diagnostic models were developed: a base model including only PSA; a multivariable model including age, PSA, DRE, prostate volume, and information on previous biopsy; and an advanced model adding PIRADS (1-5) to the multivariable model. By adding age, DRE, prostate volume and information of previous biopsies to the base model increased the area under the curve (AUC) significantly for predicting significant prostate cancer from 0.598 (95% CI: 0.541-0.654) to 0.797 (95% CI: 0.750-0.840; Fig. 1 ). Adding PIRADS (1) (2) (3) (4) (5) to the multivariable model increased the AUC significantly for predicting significant prostate cancer from 0.797 to 0.883 (95% CI: 0.849-0.916; Fig. 1 ). Figure 2 shows the regression coefficient-based nomogram derived from the advanced model. After 1 000 bootstrap resamples, the discrimination of the multivariable model was slightly higher AUC 0.819 (95% CI: 0.777-0.862). After 1 000 bootstrap resamples, the discrimination of the advanced model was also slighter higher 0.897 (95% CI: 0.868-0.928).
In external validation, the discrimination of the advanced model slightly decreased to AUC 0.864 (95% CI: 0.812-0.916). In external validation, calibration-in-the-large (regression intercept = À0.079, P = 0.67), indicated that our model slightly under-predicted the risk of significant prostate cancer. The calibration slope was 0.84 (P = 0.19 for comparison against a slope of 1, Appendix S3).
On decision curve analysis, six clinical biopsy strategies were analysed; biopsy everyone, biopsy no-one, biopsy everyone who was determined to have a risk of >10% probability of significant prostate cancer based on the PSA, multivariable and advanced model, respectively. Finally, a joined biopsy approach in which (a) those with a predicted probability of >60% based on the multivariable model are biopsied, and (b) those with a predicted probability of >15%, based on multivariable model, after performing mpMRI are biopsied. Clearly, on decision curve analysis, the advanced model suggests a net benefit compared to all other strategies for all biopsy thresholds (Fig. 3) .
The use of the multivariable and advanced model to identify men harbouring significant prostate cancer can reduce the number of unnecessary biopsies (Table 2) . At a probability on age, PSA, DRE, prostate volume, and mpMRI. Instructions: locate the patient's age at surgery on the age axis. Draw a line straight upward to the point axis to determine how many points towards the probability of significant prostate cancer the patients receives for his age. Repeat the process for each additional variable. Sum the points for each predictor. Locate the final sum on the total-point axis. Draw a line straight down to find the patient's probability of having significant prostate cancer.
© 2017 The Authors BJU International © 2017 BJU International 777 threshold of 10%, the net reduction in biopsies taken based on the multivariable and advanced models is 16% and 28% respectively, whilst missing <3% of significant prostate cancers (i.e. 2.6% of the total population would have a significant prostate cancer missed). Table 2 presents the results of different biopsy strategies using the multivariable and advanced nomogram. For every 1 000 men who are clinically indicated for biopsy, the number of avoided biopsies, number of insignificant prostate cancer diagnosed, and the number of missed significant prostate cancer are shown (Table 2) .
Discussion
The present study confirms that, although mpMRI is not routinely recommended in the diagnostic process of prostate cancer, mpMRI can reduce the rate of unnecessary biopsies and reduce the over-detection of insignificant prostate cancer. We developed and evaluated the diagnostic performance of a statistical model based on a combination of age, PSA, DRE, prostate volume, previous negative biopsy, and mpMRI. We found that the model had higher discrimination than a multivariable model including PSA, age, DRE, and prostate volume. The model predicting risk of significant prostate cancer at biopsy was well calibrated in internal and external validation, with decision analysis showing that use of the advanced model in practice would improve biopsy outcome predictions. In Figure 3 , we compared the different models. In this analysis also a conditional model was included based on (a) those with a predicted probability of >60% in the multivariable model being biopsied, and those with a probability of >15% after including mpMRI being biopsied. Although we acknowledge that these values are arbitrary, they are based on previous work [17] . Nevertheless, using different percentages (i.e. 5%, 10% or 15%) did not change the overall superiority in net benefit of the advanced model compared to all other strategies for all biopsy thresholds. shown. The conditional model is based on (a) those with a predicted probability of >60% in the full model without mpMRI being biopsied, and those with a probability of >15% after including mpMRI being biopsied. As comparison, the net benefits from a biopsy-all strategy and a biopsy-none strategy are shown. Currently, not all men benefit from prostate biopsy because of the low specificity of the current diagnostic tests (high false-positive rate), and inability to discriminate between significant and insignificant disease, resulting in a high detection rate of indolent tumours that do not need immediate treatment and probably do not need treatment at all. To address these limitations, we built an advanced model for predicting significant prostate cancer in clinical practice. Significant prostate cancer was used as the endpoint with the aim to reduce the over-detection and treatment of indolent prostate cancer. The use of this tool could aid patient counselling and decisions about whether to biopsy or not. Identification of men with significant prostate cancer allows curative prostate cancer treatments to be more effectively offered to those who benefit most [18] .
Given the decision to biopsy can be complex, cancer prediction nomograms with varying degrees of accuracy, generalisability, and validation have been developed to assist the clinician in selecting patients for biopsy. [23] [24] [25] [26] . In the present study, the addition of mpMRI to the generally used clinical factors improved predictive accuracy by 9%.
The implementation of mpMRI into a screening programme, as a second-line tool, currently appears to be the most promising technique to reduce the risk of over-detection of insignificant prostate cancer [27] . New MRI functional sequences and scanning techniques have boosted the diagnostic accuracy of mpMRI and its potential to be used as an additional tool before biopsy to improve biopsy yield [27, 28] . A recent systematic review reported accuracies of 44-87%, sensitivities of 58-97%, and specificities of 23-87% for detection of clinically significant prostate cancer using mpMRI [10] . A meta-analysis of 14 studies evaluating PIRADS reported a pooled sensitivity of 82% and pooled specificity of 82% for detection of prostate cancer with mpMRI in high-quality studies, and 84% and 75% respectively for significant prostate cancer, although some used a PIRADS threshold of 4 rather than 3, which could explain the lower sensitivity and higher specificity than in our present study [29] . Meanwhile, the high costs of mpMRI are subject to debate when evaluating the resource utility of mpMRI for the detection of significant prostate cancer. However, if the reduction in unnecessary biopsies is considerable and reduction in the detection of clinically lowrisk prostate cancer is~20%, mpMRI would be expected to lead to lower costs and higher quality of life when longerterm costs of follow-up and treatment are considered [30] .
Previous analysis of the development population showed good correlation of the ROI on mpMRI and detection of significant prostate cancer. In the present analysis, the MRI-positive ROI were assessed and correlated with the location of the positive biopsy to assess anatomical concordance or mismatch with cores in the same zone and in zones with direct contact as considered part of the same lesion. Overall, anatomical concordance of mpMRI with an 18-region biopsy template was found in 97% of men diagnosed with significant prostate cancer, with only 3% of these men a true positive biopsy but anatomical mismatch with the MRI-positive region. In other words, the advanced model presented in the present study that appears to predict the probability of significant prostate cancer on mpMRI-targeted biopsy only seems to be adequate.
Despite the strengths, our present study is not devoid of limitations. Firstly, patients were biopsied using transperineal mapping biopsies (median of 30 cores), which is not the routine biopsy strategy in most institutions. However, the results of biopsy schemes involving saturation biopsies appear to have a higher concordance rate with results from prostatectomy than a scheme involving <12 cores, indicating that our nomogram predicts the actual risk of significant prostate cancer, in contrast to the existing prediction nomograms that are derived from a six or eight core approach [19, 20, 31] , in which the reference test is less reliable. Secondly, the validation population was a retrospective cohort and thus biased by the inherent limitations of such a study design, although it was a consecutive cohort (and thus less at risk of selection bias). Furthermore, the validation cohort differed slightly from the development population with an unusually high prevalence of significant prostate cancer, and perhaps further validation in a population with a lower prevalence of significant cancer would be of value. Also, the median number of biopsies per patient differed among the development and the validation population. Intuitively, adding more biopsy cores to prostate areas not sampled is supposed to increase cancer detection; however, at present it is unclear whether mpMRI-guided saturation biopsies compared to an mpMRI-guided extended prostate biopsy scheme reveal superiority in the detection of prostate cancer [32] . Moreover, different mpMRIs were used in the present study, although, the diagnostic performance was not significantly different between the 1.5-and 3.0-T magnet, OR 0.84 (95% CI: 0.48-1.47, P = 0.53). Also, different targeting methods (MRI/TRUS fusion or cognitive biopsy) were used; however, statistical analyses showed no relevant differences in cancer detection between the two methods, probably due to the small number of additional target biopsies next to the mapping biopsies.
Furthermore, in developing the multivariable model (model without mpMRI), the reference biopsies had been performed with the knowledge of the mpMRI findings, which may have informed biopsy locations. This might have overestimated the diagnostic performances of the multivariable model. Also, the study cohort was ethnically relatively homogeneous (Australian with mostly Eastern and Western European ethnicity), which precludes making inferences about the effects of race. Finally, experienced radiologists interpreted the mpMRIs in the development and validation cohort and the results may thus primarily reflect those of a high-volume institution, which may not be applicable to less experienced radiologists. Despite these limitations, our nomogram is the first externally validated multivariable tool that incorporates mpMRI and provides risk profile-based threshold values as indicators for a prostate biopsy. This nomogram could be useful in the clinical decision-making process of patients considered for prostate biopsy.
Conclusions
A multivariable risk stratification that includes the imaging modality mpMRI is a much more powerful risk-stratification tool than the PSA test alone or the currently used multivariable prostate cancer prediction nomograms. The present study confirms that a model incorporating mpMRI improves clinical decision making about whether or not to biopsy a patient who is otherwise indicated for biopsy. Using a 10% nomogram-derived risk as the threshold for biopsy would result in 28% of biopsies being avoided whilst missing significant cancer in only 2.6% of the population. This diagnostic strategy is a promising approach to reduce the risk of over-detection of non-significant prostate cancer and improve the early detection of clinically significant prostate cancer.
